Key result
Chemotherapy with paclitaxel and hemostatic radiotherapy were inefficient for an 83-year-old man with gingival and palatine tonsil angiosarcoma, who died seven months after symptom onset.
Case Report (n=1)
This case report highlights an extremely rare presentation of intra-oral angiosarcoma involving the gingiva and palatine tonsils, demonstrating a rapid and fatal clinical course despite treatment.
Alerts clinicians to rare gingival/tonsillar angiosarcoma in bleeding lesions; extends intraoral sites but leaves management open.
Angiosarcomas are one of the rarest subtypes of sarcomas; those are malignant vascular tumors arising from vascular endothelial cells. Occurrence of intra-oral angiosarcoma is extremely rare (0.0077% of all cancers in Europe). We present here, to our knowledge, the first case of a 83-year-old man with gingival and both palatine tonsils localization of a grade-two angiosarcoma discovered after a two months history of a painful lesion followed by hematoma and spontaneous bleeding. Chemotherapy with paclitaxel and hemostatic radiotherapy were inefficient and he died seven months after the first symptoms. It is essential to use the vascular markers, such as CD34, CD31, ERG and FLI1, for a correct histological diagnosis, which remains difficult because it displays a wide range of morphological appearances and multiple patterns may be present in the same tumor. The main prognostic factors are chronic pre-existing lymphedema and tumor size greater than five centimeters. Malignancy grade and stage classification should be provided in all cases in which this is feasible because of predictive meaning. When possible, wide surgical resection with negative margins remains the cornerstone for the treatment of localized angiosarcomas, but despite the improvement of surgical techniques the prognosis is poor with more than half of patients died within the first year. Adjuvant radiotherapy is the standard treatment of high-grade (two and three), deep lesions, regardless of size, because it improved the local recurrence-free survival. For advanced disease, if possible, metastasectomy should be considered. The first-line chemotherapy with doxorubicin or paclitaxel should be discussed compared to best supportive care according to patient comorbidities and preference.
No takes yet. Share an insight, caveat, or question.
Chamberland et al. (2016) conducted a case report in Angiosarcoma (gingival and palatine tonsils) (n=1). Chemotherapy with paclitaxel and hemostatic radiotherapy was evaluated on Treatment response and survival. Chemotherapy with paclitaxel and hemostatic radiotherapy were inefficient for an 83-year-old man with gingival and palatine tonsil angiosarcoma, who died seven months after symptom onset.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: